Eagle Pharmaceuticals

Courtesy of Eagle Pharmaceuticals
  • Previous Rank
  • Revenue 3 Yr Annual Growth Rate
    109
  • Revenue 3 Yr Growth Rank
    1
  • EPS 3 Yr Annual Growth Rate
    392
  • EPS 3 Yr Growth Rank
    1
  • Total Return 3 Yr Annual Rate
    -2
  • Total Return 3 Yr Rank
    97

In an era of drug development that’s produced seeming miracles like gene editing and cancer immunotherapy, the business of “injectables” may come across as quaint. But there’s nothing boring about coming up with new ways of mixing and administering therapies in a way that helps patients in novel ways. And there’s certainly nothing boring about a 36% return on shareholder investment in 2018 alone. Eagle Pharmaceuticals is a standout among its specialty pharmaceutical peers for investors, no matter how bread-and-butter its aspirations may seem.

Company Information

LocationWoodcliff Lake, N.J.
IndustryPharmaceuticals
SectorHealth Care
Current Streak-
Years on List1
CEOScott Tarriff
Websitewww.eagleus.com

Revenue, Net Income

Revenue past four quarters ($M)$207
Net Income past four quarters ($M)$32

Growth Rates and Ranks

Revenue 3 Yr Growth Rank1
Revenue 3 Yr Annual Growth Rate109%
EPS 3 Yr Growth Rank1
EPS 3 Yr Annual Growth Rate392%
Total Return 3 Yr Rank97
Total Return 3 Yr Annual Rate-2%
Beat S&P 500 (11.9%)no
P/E Ratio32